Combinatory statuses of tumor stromal percentage and tumor infiltrating lymphocytes as prognostic factors in stage III colorectal cancers

2022 ◽  
Author(s):  
Hye‐Yeong Jin ◽  
Seung‐Yeon Yoo ◽  
Ji‐Ae Lee ◽  
Xinayu Wen ◽  
Younghoon Kim ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Tumor Infiltrating Lymphocytes ◽  
Stage Iii ◽  
Colorectal Cancers ◽  
Infiltrating Lymphocytes

scholarly journals PD-L1 and IL17 expression in tumor infiltrating lymphocytes are opposite prognostic factors in glioblastoma

2016 ◽  
Vol 27 ◽  
pp. vi104
Author(s):  
E. Bronsart ◽  
V. Derangere ◽  
M. Boone ◽  
B. Chauffert ◽  
F. Ghiringhelli
Keyword(s):  
Prognostic Factors ◽  
Tumor Infiltrating Lymphocytes ◽  
Infiltrating Lymphocytes

Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma

2007 ◽  
Vol 56 (11) ◽  
pp. 1853-1860 ◽  
Author(s):  
Amir Khammari ◽  
Jean-Michel Nguyen ◽  
Marie Christine Pandolfino ◽  
Gaëlle Quereux ◽  
Anabelle Brocard ◽  
...  
Keyword(s):  
Adjuvant Therapy ◽  
Adoptive Transfer ◽  
Tumor Infiltrating Lymphocytes ◽  
Stage Iii ◽  
Melanoma Tumor ◽  
Long Term Follow Up ◽  
Stage Iii Melanoma ◽  
Infiltrating Lymphocytes

scholarly journals Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates

BMC Cancer ◽  
2010 ◽  
Vol 10 (1) ◽  
Author(s):  
Alessandra Estrela-Lima ◽  
Márcio SS Araújo ◽  
João M Costa-Neto ◽  
Andréa Teixeira-Carvalho ◽  
Stella M Barrouin-Melo ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Survival Rates ◽  
Tumor Infiltrating Lymphocytes ◽  
Mammary Carcinomas ◽  
Infiltrating Lymphocytes

Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN–driven CCL5 and CXCL10

2021 ◽  
Vol 218 (9) ◽  
Author(s):  
Courtney Mowat ◽  
Shayla R. Mosley ◽  
Afshin Namdar ◽  
Daniel Schiller ◽  
Kristi Baker
Keyword(s):  
T Cells ◽  
Mismatch Repair ◽  
Tumor Immunity ◽  
Cd8 T Cells ◽  
Tumor Infiltrating Lymphocytes ◽  
Colorectal Cancers ◽  
Type I ◽  
Type I Ifn ◽  
Dna Mismatch ◽  
Infiltrating Lymphocytes

Colorectal cancers (CRCs) deficient in DNA mismatch repair (dMMR) contain abundant CD8+ tumor-infiltrating lymphocytes (TILs) responding to the abundant neoantigens from their unstable genomes. Priming of such tumor-targeted TILs first requires recruitment of CD8+ T cells into the tumors, implying that this is an essential prerequisite of successful dMMR anti-tumor immunity. We have discovered that selective recruitment and activation of systemic CD8+ T cells into dMMR CRCs strictly depend on overexpression of CCL5 and CXCL10 due to endogenous activation of cGAS/STING and type I IFN signaling by damaged DNA. TIL infiltration into orthotopic dMMR CRCs is neoantigen-independent and followed by induction of a resident memory-like phenotype key to the anti-tumor response. CCL5 and CXCL10 could be up-regulated by common chemotherapies in all CRCs, indicating that facilitating CD8+ T cell recruitment underlies their efficacy. Induction of CCL5 and CXCL10 thus represents a tractable therapeutic strategy to induce TIL recruitment into CRCs, where local priming can be maximized even in neoantigen-poor CRCs.

Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma

2002 ◽  
Vol 51 (10) ◽  
pp. 539-546 ◽  
Author(s):  
Brigitte Dréno ◽  
Jean-Michel Nguyen ◽  
Amir Khammari ◽  
Marie Pandolfino ◽  
Marie Tessier ◽  
...  
Keyword(s):  
Adjuvant Therapy ◽  
Randomized Trial ◽  
Adoptive Transfer ◽  
Tumor Infiltrating Lymphocytes ◽  
Stage Iii ◽  
Melanoma Tumor ◽  
Stage Iii Melanoma ◽  
Infiltrating Lymphocytes

scholarly journals Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant Melanoma

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Wei Li ◽  
Linping Xu ◽  
Yaomei Wang ◽  
Lingdi Zhao ◽  
Daniel B. Kellner ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Disease Free Survival ◽  
Tumor Infiltrating Lymphocytes ◽  
Surgical Excision ◽  
Stage Iii ◽  
Time Points ◽  
Measured Time ◽  
Resected Stage ◽  
Infiltrating Lymphocytes ◽  
Better Than

Background. This study aims to explore the efficacy of tumor-infiltrating lymphocytes (TIL) along with interferon-α (IFN-α) to treat stage III malignant melanoma (MM) patients in China. Methods. Between May 2010 and October 2014, 77 patients of stage III MM who underwent surgery were collected in this study. These patients were divided into two groups: patients who received TIL + IFN-α ± RetroNectin-activated cytokine-induced killer cells (R-CIK) in Arm 1 (n=27) and IFN-α ± R-CIK in Arm 2 (n=50) as adjuvant therapy. The primary endpoints were disease-free survival (DFS) time and DFS rates measured at time points of 1, 2, and 3 years. The secondary endpoints were overall survival (OS) rates measured at time points of 1, 2, 3, and 5 years as well as OS as evaluated by Kaplan-Meier. Results. Our results indicated that the median DFS and OS in Arm 1 were significantly better than those in Arm 2. The data also demonstrated that DFS rate and OS rates in Arm 1 were significantly better than those in Arm 2 at all measured time points. Conclusion. Patients who undergo surgical excision of stage III MM appear to enjoy prolonged DFS and OS when treated with TIL + IFN-α compared to IFN-α alone.

Sign in / Sign up

Export Citation Format

Share Document